Drug Profile
Research programme: cancer therapeutics - Ikena Oncology
Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Kyn Therapeutics
- Developer Ikena Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action Aryl hydrocarbon receptor antagonists; Kynurenine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Cancer in USA
- 03 Dec 2019 Kyn Therapeutics is now called Ikena Oncology
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb